The development of tyrosine kinase inhibitors for the treatment of inflammation and malignant disease. (2004–2007)

Through the combination of expertise from the Industry partner and the Hume group this project aims to develop specific inhibitors of the CSF-1 receptor protein tyrosine kinase in order to demonstrate their efficacy as modulators of CSF-1 dependent macrophage and tumour cell function in vitro. The expected outcome will be a lead set of targets which can be further assessed for therapeutic potential in clinical trials.
Grant type:
ARC Linkage Projects
  • Professor
    Mater Research Institute-UQ
    Faculty of Medicine
  • NHMRC Leadership Fellow - GL
    Institute for Molecular Bioscience
    Affiliate NHMRC Leadership Fellow
    School of Chemistry and Molecular Biosciences
    Faculty of Science
Funded by:
Australian Research Council